Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2515-2520

  Fofana, D B ^a   Soulie, C ^a   Maiga, A I ^b   Fourati, S ^a   Malet, I ^a   Wirden, M ^a   Tounkara, A ^b   Traore, H A ^b   Calvez, V ^a   Marcelin, A G ^a   Lambert Niclot, S ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Université des Sciences des Techniques et des Technologies de Bamako   (Mali)

Author keywords

Genetic barrier; Subtype B; Subtype CRF02_AG

Indexed keywords

AMINO ACID; ETRAVIRINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CODON; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; VIRUS GENE; VIRUS RESISTANCE;

GENETIC BARRIER; SUBTYPE B; SUBTYPE CRF02_AG;

ANTI-HIV AGENTS; CONSERVED SEQUENCE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HUMANS; MUTATION, MISSENSE; NITRILES; PYRIDAZINES; PYRIMIDINES;

EID: 84886296431     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt251     Document Type: Article

References (20)

1. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
2. Ghosn J, Chaix M-L, Delaugerre C. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009; 11: 165-73.
3. Department of Health and Human services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www. aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf?bcsi_scan_ CBA24F92DB3F63E2=0&bcsi_scan_filename=adultandadolescentgl.pdf (21 May 2013, date last accessed).
4. Andries K, Azijn H, Thielemans T et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48: 4680-6.
5. Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
6. Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
7. Johnson VA, Calvez V, Gunthard HF et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156-64.
8. Sanford M. Rilpivirine. Drugs 2012; 72: 525-41.
9. Molina JM, Cahn P, Grinsztejn B et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-46.
10. Vingerhoets J, Rimsky L, Van Eygen V et al. Preexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic response. Antivir Ther 2013; 18: 253-6.
11. Anta L, Llibre JM, Poveda E et al. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS 2013; 27: 81-5.
12. AzijnH,Tirry I,Vingerhoets J et al. TMC278,anext-generationnonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54: 718-27.
13. Gotte M. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. Curr Opin Virol 2012; 2: 644-50.
14. van de Vijver DA, Wensing AM, Angarano G et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 41: 352-60.
15. Maiga AI, Malet I, Soulie C et al. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir Ther 2009; 14: 123-9.
16. Nguyen HL, Ruxrungtham K, Delaugerre C. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B. Intervirology 2012; 55: 287-95.
17. Asahchop EL, Oliveira M, Wainberg MA et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 2011; 55: 600-7.
18. Lai MT, Lu M, Felock PJ et al. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2010; 54: 4812-24.
19. Marcelin AG, Descamps D, Tamalet C et al. Emerging mutations and associated factors in patients displaying treatment failure on an etravirinecontaining regimen. Antivir Ther 2012; 17: 119-23.
20. Maiga AI, Descamps D, Morand-Joubert L et al. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-BHIV-1 subtypes.Antimicrob AgentsChemother2010;54: 728-33.